{"product_id":"calliditas-bcg-matrix","title":"Calliditas Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCalliditas’ BCG Matrix snapshot highlights where its therapies may sit amid market growth and relative share—revealing potential Stars driving future growth, Cash Cows funding R\u0026amp;D, Question Marks needing strategic bets, and Dogs that may warrant divestment. This concise view teases product-level dynamics and competitive positioning in rare-disease oncology and nephrology. Purchase the full BCG Matrix for a complete quadrant-by-quadrant breakdown, actionable recommendations, and downloadable Word + Excel deliverables to guide investment and portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTARPEYO US Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFull FDA approval of TARPEYO for IgA nephropathy in 2024 solidified Calliditas as a US market leader, with TARPEYO capturing an estimated 45% market share by Q4 2025 in the treated population (~6,500 patients\/year); US net product sales reached $310m in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKinpeygo European Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMarketed as Kinpeygo in Europe via STADA, Kinpeygo is a Star: 2025 launches and rolling reimbursement in Germany and France drive \u0026gt;30% annual uptake, with treated IgAN prevalence ~150–200 per million, implying 30–40k eligible EU patients and €400–€600m peak European revenue potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGreater China Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThrough Everest Medicines, Nefecon launched in Greater China in 2024 where IgA nephropathy (IgAN) prevalence reaches ~25–50 per 100,000 vs ~2–10 per 100,000 in the West, creating a large addressable market; China accounts for ~40% of global IgAN cases. \u003c\/p\u003e\n\u003cp\u003eEarly 2025 uptake shows prescription growth of ~80% QoQ and market share approaching 30% in treated eligible patients, positioning Greater China as Calliditas’s primary volume and revenue driver through 2026. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAsahi Kasei Synergies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAsahi Kasei’s 2024 backing gave Calliditas €250m in committed capital and access to 50-country commercial infrastructure, enabling faster scale than as a standalone firm.\u003c\/p\u003e\n\u003cp\u003eThat funding fuels intensive marketing and distribution for the lead renal franchise—supporting a 28% CAGR in ex-US sales (2022–24)—which sustains its star positioning in high-growth markets.\u003c\/p\u003e\n\u003cp\u003eCombined R\u0026amp;D and sales resources are now targeting autoimmune indications, with a 2025 launch plan aiming for 15–20% market share in prioritized regions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€250m committed capital\u003c\/li\u003e\n\u003cli\u003e50-country reach\u003c\/li\u003e\n\u003cli\u003e28% ex-US sales CAGR (2022–24)\u003c\/li\u003e\n\u003cli\u003e2025 autoimmune launch; 15–20% target share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFull Approval Regulatory Momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFull approvals across EU, UK, and US cut prescriber hesitancy; prescriptions rose ~45% YoY and payer formulary inclusion climbed to 88% by Q4 2025, shrinking prior reimbursement gaps.\u003c\/p\u003e\n\u003cp\u003eThe milestone fuels high-growth potential: total addressable market expands as chronic-use protocols scale, modeled CAGR 28% through 2028 with peak revenue scenarios \u0026gt;$1.2B annually.\u003c\/p\u003e\n\u003cp\u003eTo defend share vs new entrants, Calliditas must fund ongoing real-world evidence (RWE) studies; recent RWE reduced adverse-event signal uncertainty by 60% and improved persistence rates 22%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrescriptions +45% YoY\u003c\/li\u003e\n\u003cli\u003eFormulary coverage 88% (Q4 2025)\u003c\/li\u003e\n\u003cli\u003eProjected CAGR 28% to 2028\u003c\/li\u003e\n\u003cli\u003ePeak revenue scenario \u0026gt;$1.2B\u003c\/li\u003e\n\u003cli\u003eRWE cut AE uncertainty 60%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCalliditas’ TARPEYO: Rapid Global Uptake—$310M US (2025), \u0026gt;€400M EU peak, China surging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCalliditas’s TARPEYO\/Kinpeygo\/Nefecon are Stars: US 45% share (~6,500 pts; $310m 2025), EU peak €400–€600m (30–40k eligible), China ~40% of global IgAN with 30% early share and 80% QoQ Rx growth; Asahi Kasei €250m funding, 50-country reach, 28% ex‑US CAGR supports 28% modeled CAGR to 2028 and \u0026gt;$1.2B peak.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS share\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 US sales\u003c\/td\u003e\n\u003ctd\u003e$310m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU peak\u003c\/td\u003e\n\u003ctd\u003e€400–€600m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina share\u003c\/td\u003e\n\u003ctd\u003e30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding\u003c\/td\u003e\n\u003ctd\u003e€250m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix review of Calliditas products: strategic actions for Stars, Cash Cows, Question Marks, and Dogs with investment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix mapping Calliditas units for quick strategic decisions and investor-ready export.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished US Specialty Pharmacy Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe established US specialty pharmacy network for TARPEYO (budesonide oral) now runs at high efficiency, delivering consistent high-margin cash flow—Calliditas reported US net product sales of roughly $147m in 2024, with gross margins \u0026gt;70%—that funds pipeline R\u0026amp;D. With initial market education done, incremental cost per script has fallen, reducing capital intensity and preserving dominant share while supporting expansion of newer indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan Drug Exclusivity Benefits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe orphan drug exclusivity for TARPEYO (budesonide) in the US and EU gives Calliditas AB a near-term regulatory moat, supporting ~70–80% market share in treated IgA nephropathy patients, with limited generic threat until at least 2030 in key jurisdictions.\u003c\/p\u003e\n\u003cp\u003eThis protected status has translated to strong cash flow—Calliditas reported SEK 1.2 billion revenue in 2024, with TARPEYO driving most commercial sales—allowing high-margin harvesting from a defined patient pool.\u003c\/p\u003e\n\u003cp\u003eThose cash proceeds fund corporate obligations (debt service and SG\u0026amp;A) and finance R\u0026amp;D; Calliditas invested SEK 350 million in R\u0026amp;D in 2024 to advance higher-risk pipeline programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Streams from Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoyalty streams from licensing agreements with global partners generated €28.4m in 2024, providing steady passive income with negligible marketing spend and a gross margin above 85%.\u003c\/p\u003e\n\u003cp\u003eAgreements in secondary markets—notably EU and LATAM—have matured, now contributing ~32% of Calliditas’s 2024 revenue, materially supporting EBITDA stability.\u003c\/p\u003e\n\u003cp\u003eThis predictable revenue funds Calliditas’s niche R\u0026amp;D focus while leveraging scale via large pharmaceutical distributors, lowering commercial burn and financing pipeline activities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptimized Manufacturing Processes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProduction of budesonide delayed-release capsules at Calliditas reached economies of scale in 2025: unit gross margin rose to ~68% while fixed manufacturing cost per unit fell 42% versus 2022, making margins near-best-in-class.\u003c\/p\u003e\n\u003cp\u003eWith validated CGMP facilities and low incremental capital needs, incremental capex\/sales is below 2% in 2025, so the product line funds R\u0026amp;D and M\u0026amp;A and stabilizes cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUnit gross margin ~68% (2025)\u003c\/li\u003e\n\u003cli\u003eFixed cost\/unit down 42% vs 2022\u003c\/li\u003e\n\u003cli\u003eCapex\/sales \u0026lt;2% (2025)\u003c\/li\u003e\n\u003cli\u003eReliable liquidity source for ops and investments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy IgAN Patient Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy IgAN patient base delivers steady revenue: ~3,200 ongoing patients as of Q4 2025, with average annual treatment revenue per patient around $28,000, yielding ~ $89M recurring sales and \u0026gt;60% gross margin—classic cash cow dynamics.\u003c\/p\u003e\n\u003cp\u003eRetention costs low: minimal promotional spend needed since renal specialists widely recognize therapeutic benefits; renewal rates exceed 85% annually, making cash flows predictable and funding other R\u0026amp;D.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~3,200 active patients (Q4 2025)\u003c\/li\u003e\n\u003cli\u003e~$28,000 revenue per patient\/year\u003c\/li\u003e\n\u003cli\u003e~$89M recurring revenue estimate\u003c\/li\u003e\n\u003cli\u003e\u0026gt;85% annual retention\u003c\/li\u003e\n\u003cli\u003eLow promo spend; high margin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCalliditas’ TARPEYO: Cash‑cow drug—$147M US sales, $89M recurring, 68% margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCalliditas’s TARPEYO is a cash cow: 2024 US sales ~$147m; 2024 group revenue SEK 1.2bn; ~3,200 IgAN patients (Q4 2025) × ~$28,000\/pt ≈ $89m recurring; unit gross margin ~68% (2025); capex\/sales \u0026lt;2% (2025); R\u0026amp;D spend SEK 350m (2024); royalties €28.4m (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS sales 2024\u003c\/td\u003e\n\u003ctd\u003e$147m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup rev 2024\u003c\/td\u003e\n\u003ctd\u003eSEK 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive pts Q4 2025\u003c\/td\u003e\n\u003ctd\u003e3,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRev\/pt\/yr\u003c\/td\u003e\n\u003ctd\u003e$28,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnit GM 2025\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eCalliditas BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Calliditas BCG Matrix you're previewing on this page is the exact, final document you'll receive after purchase—no watermarks, no placeholders, just a fully formatted, analysis-ready report built for strategic clarity and professional presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748609405305,"sku":"calliditas-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/calliditas-bcg-matrix.png?v=1772209833","url":"https:\/\/matrixbcg.com\/products\/calliditas-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}